FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655604> ?p ?o ?g. }

• W4385655604 endingPage "e23167d8" @default.
• W4385655604 startingPage "e23167d8" @default.
• W4385655604 abstract "Topic: 15. Myeloproliferative neoplasms - Biology & Translational Research Background: Coexistence of myeloid and lymphoid neoplasm is extremely rare. Previous reports indicates clonal independence of myeloproliferative neoplasm (MPN) and chronic lymphocytic leukemia (CLL) occurrence. When such rare coexistence occur, in most reported cases lymphoid neoplasm has an indolent clinical course as well as low-risk biological profile. Aims: Presenting treatment challenges in very rare case of our patient initially diagnosed with essential thrombocythemia (ET) and free years afterwards with CLL. Methods: We diagnosed ET after bone marrow biopsy, clinical, and laboratory findings, cytogenetic analyses and JAK2V617F mutation status. Regular check-ups after Hydroxyurea was introduced was maintained. Subsequent CLL was diagnosed following clinical, radiography (computerized tomography of chest, abdomen and pelvis) findings as well as immunophenotyping of peripheral lymphocytes by flow cytometry. Chemotherapy effect of CLL treatment was confirmed via physical finding, laboratory, and radiography post-treatment findings. Results: Our female patient, aged 57, was initially diagnosed with ET with normal karyotype, as well as confirmed JAK2V617F mutation in March 2015. Initial treatment with Hydroxyurea (HU) 2x500mg per day was introduced, after assessment of cerebrovascular risk factors presence, as well as leukocytosis degree on presentation. Three years later, triggered by progressive leukocytosis (26.4x109/L) with lymphocytosis (91%), hematological reevaluation was performed with confirmation of CLL, staged as II CS (Rai), with immunophenotype analysis revealing CLL score 5, CD38-. After further clinical assessment, HU therapy continued with CLL on “watch and wait”. In February 2020, bone marrow biopsy was performed, as leukocytosis progression was confirmed, reaching as much as 60x109/l, pathohistological finding revealed 60% lymphocytes infiltration. Further diagnostics showed normal FISH finding, cytogenetic analysis detected normal karyotype. Due to regular platelet count maintenance, HU treatment was discontinued. In less than six months period leukocytes “doubling time” was detected, with leukocytes count peak of 155x109/L. Also progressive lymphadenopathy was confirmed with splenomegaly that was previously undetected. At this point CLL treatment with Obinutuzumab-Chlormabucil was introduced, six cycles in total, with complete remission effect. Less than a year later, HU was re-introduced due to progressive thrombocytosis, whereas regular leukocytes count and leukocytes formula maintained. Summary/Conclusion: Patient with MPN was diagnosed three years later with CLL that, following two year period of “watch and wait”, demanded intensive chemotherapy. Therefore, in our experience, regular follow-up of patients with myeloid and lymphoid neoplasms coexistence is necessary, primarily because of carrying out treatment of more active malignancy, in accordance to current findings. Because of increased myelosuppressive effect risk if combined treatment is performed, successive therapy is advised. Keywords: Thrombocythemia" @default.
• W4385655604 created "2023-08-09" @default.
• W4385655604 creator A5023234048 @default.
• W4385655604 creator A5037966102 @default.
• W4385655604 creator A5043296389 @default.
• W4385655604 creator A5044848093 @default.
• W4385655604 creator A5056545510 @default.
• W4385655604 creator A5068023110 @default.
• W4385655604 date "2023-08-01" @default.
• W4385655604 modified "2023-10-16" @default.
• W4385655604 title "PB2180: TREATMENT CHALLENGES OF COEXISTING MYELOID AND LYMPHOID NEOPLASM- A CASE REPORT" @default.
• W4385655604 doi "https://doi.org/10.1097/01.hs9.0000975472.23167.d8" @default.
• W4385655604 hasPublicationYear "2023" @default.
• W4385655604 type Work @default.
• W4385655604 citedByCount "0" @default.
• W4385655604 crossrefType "journal-article" @default.
• W4385655604 hasAuthorship W4385655604A5023234048 @default.
• W4385655604 hasAuthorship W4385655604A5037966102 @default.
• W4385655604 hasAuthorship W4385655604A5043296389 @default.
• W4385655604 hasAuthorship W4385655604A5044848093 @default.
• W4385655604 hasAuthorship W4385655604A5056545510 @default.
• W4385655604 hasAuthorship W4385655604A5068023110 @default.
• W4385655604 hasBestOaLocation W43856556041 @default.
• W4385655604 hasConcept C126322002 @default.
• W4385655604 hasConcept C142724271 @default.
• W4385655604 hasConcept C196166836 @default.
• W4385655604 hasConcept C203014093 @default.
• W4385655604 hasConcept C2775934546 @default.
• W4385655604 hasConcept C2778837598 @default.
• W4385655604 hasConcept C2778923028 @default.
• W4385655604 hasConcept C2779282312 @default.
• W4385655604 hasConcept C2780007613 @default.
• W4385655604 hasConcept C2780076729 @default.
• W4385655604 hasConcept C2780126324 @default.
• W4385655604 hasConcept C2781057849 @default.
• W4385655604 hasConcept C2781107747 @default.
• W4385655604 hasConcept C553184892 @default.
• W4385655604 hasConcept C71924100 @default.
• W4385655604 hasConceptScore W4385655604C126322002 @default.
• W4385655604 hasConceptScore W4385655604C142724271 @default.
• W4385655604 hasConceptScore W4385655604C196166836 @default.
• W4385655604 hasConceptScore W4385655604C203014093 @default.
• W4385655604 hasConceptScore W4385655604C2775934546 @default.
• W4385655604 hasConceptScore W4385655604C2778837598 @default.
• W4385655604 hasConceptScore W4385655604C2778923028 @default.
• W4385655604 hasConceptScore W4385655604C2779282312 @default.
• W4385655604 hasConceptScore W4385655604C2780007613 @default.
• W4385655604 hasConceptScore W4385655604C2780076729 @default.
• W4385655604 hasConceptScore W4385655604C2780126324 @default.
• W4385655604 hasConceptScore W4385655604C2781057849 @default.
• W4385655604 hasConceptScore W4385655604C2781107747 @default.
• W4385655604 hasConceptScore W4385655604C553184892 @default.
• W4385655604 hasConceptScore W4385655604C71924100 @default.
• W4385655604 hasIssue "S3" @default.
• W4385655604 hasLocation W43856556041 @default.
• W4385655604 hasLocation W43856556042 @default.
• W4385655604 hasOpenAccess W4385655604 @default.
• W4385655604 hasPrimaryLocation W43856556041 @default.
• W4385655604 hasRelatedWork W1963972403 @default.
• W4385655604 hasRelatedWork W1987927613 @default.
• W4385655604 hasRelatedWork W2011378064 @default.
• W4385655604 hasRelatedWork W2369117338 @default.
• W4385655604 hasRelatedWork W2580540396 @default.
• W4385655604 hasRelatedWork W3004722183 @default.
• W4385655604 hasRelatedWork W3032513420 @default.
• W4385655604 hasRelatedWork W3192200738 @default.
• W4385655604 hasRelatedWork W4283075020 @default.
• W4385655604 hasRelatedWork W4385655604 @default.
• W4385655604 hasVolume "7" @default.
• W4385655604 isParatext "false" @default.
• W4385655604 isRetracted "false" @default.
• W4385655604 workType "article" @default.